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ABSTRACT 
A miniaturized, high-throughput assay was optimized to screen polymer-drug solid dispersions using a 2-D Ink-jet printer. By simply printing 
nanoliter amounts of polymer and drug solutions onto an inert surface, drug:polymer micro-dots of tunable composition were produced in an easily-
addressable micro-array format. The amount of material printed for each dried spot ranged from 25 ng to 650 ng. These arrays were used to assess 
the stability of drug:polymer dispersions with respect to recrystallization, using polarized light microscopy. One array with a panel of 6 drugs 
formulated at different ratios with Poly (vinylpyrrolidone-vinyl acetate) copolymer (PVPVA) was developed to estimate a possible bulk (gram-
scale) approximation threshold from the final printed nano amount of formulation. Another array was printed at a fixed final amount of material to 
establish a literature comparison of one drug formulated with different commercial polymers for validation. This new approach may offer significant 
efficiency in pharmaceutical formulation screening, with each experiment in the nano-micro-array format requiring from 3 up to 6 orders of 
magnitude lower amounts of sample than conventional screening methods. 
INTRODUCTION  
Due in part to the use of high-throughput and combinatorial screening approaches in drug discovery development pipelines, over 40% of APIs 
(Active Pharmaceutical Ingredients) result in poorly water soluble highly permeable candidates, i.e. assigned to CLASS II according to the 
Biopharmaceutics Classiﬁcation System (BCS)1. High lipophilicity linked with markedly low water solubility (≤ 1µg/ml) limits formulation 
approaches, clinical applications and marketability because of low dissolution and bioavailability of new APIs. 1,2 A variety of formulation 
methodologies have been investigated to overcome the problem of poor aqueous solubility, 1 amongst them, amorphous solid dispersions have 
been considered one of the most promising strategies.3,4  Taking the broad concept of a solid dispersion, the drug is molecularly dispersed in an 
inert carrier, commonly a hydrophilic polymer to give an amorphous presentation of the drug to maximize aqueous apparent solubility and 
dissolution rate.5 In particular, amorphous drugs show a higher solubility and better dissolution profile compared to their crystal forms.6  Despite 
the advantages of solid dispersions, the number of available marketed products remain low due to a number of issues including scale-up and 
physicochemical instability of formulations that lead to phase segregation and possible further recrystallization of the API, particularly during the 
storage period. In a successful solid dispersion the polymer not only stabilizes the amorphous drug state against recrystallization but also 
improves the rate of dissolution of the API.7 Developing such dispersions can also be difficult1,8 both due to the timescales involved for 
assessment of stability and the preparation of solid dispersions using realistic large scale methods.  These approaches such as melt extrusion and 
spray-freeze drying, can require a substantial amount of carrier-API combinations that can be time consuming, costly and end up with batches 
with different physicochemical properties.9,10 In addition, the stability of the amorphous state of drugs in a solid dispersion can be affected by the 
ease by which the APIs themselves undergo recrystallization. In relation to this, Taylor’s group reported a further API categorization.11,12 Drug-
like organic molecules can be classified according to their crystallization tendencies. Classification can be determined either by solvent 
evaporation12 following deposition e.g. by spin-coating or by monitoring the crystallization behaviour of the amorphous forms from the 
undercooled melt by DSC.11,13 These two methods allow the classification of molecules into three groups: the easily crystallizing non-Glass 
formers GFAI and the Glass-formers (GFAII and GFAIII). GFAII shows substantial crystallization only upon 7 days of storage while GFAIII 
shows either little crystallization or no crystallization at all. While some optimization may be related just to formulation, the polymer itself is also 
a key parameter because of the need for physicochemical miscibility between drug and polymer8 which needs to be determined and optimized. 
Assessment methods commonly present in the pharmaceutical-related literature are usually based on trial and error evaluations employing a single 
model drug against a small range of polymers.8 Key analytical techniques,1 such as TGA, DSC and XRPD are routinely adopted to evaluate 
sample stability, drug recrystallization and thus, the amorphous state of the drug. These assessments may require samples to be prepared on a 
milligram to gram scale. The analyses coupled with selection and validation of methods to produce the dispersion are quite inefficient if not 
properly combined14 and there are no reliable methods for predicting the miscibility of a large library of drug:polymer solid dispersions. In view 
of the potential of polymer dispersions as a suitable formulation, and the increasing prevalence of large poorly soluble drug molecules, it would 
be useful to have a better screening process.8,9,10 In this regard, Taylor’s group8 reported an elegant small scale screening method, based on spin 
coating of 200 µl of polymer-drug solutions onto coverslips (at concentration of 0.2-0.3 M12, thus, approximately 10-20 mg of a drug with 250-
500 g/mol molecular weight for each sample). The ability of 7 chemically diverse polymers to inhibit the crystallization of 8 drugs prone to quick 
crystallization was tested. They concluded that miniaturized screening can be adopted as a powerful technique to evaluate the role of drug-
polymer chemistry in the stabilization of amorphous solid dispersions. Nevertheless, there are some limitations of this method, such as the storage 
space for all the used coverslips, difficulty in automating the sample preparation and the control of the exact amount of materials deposited on the 
coverslips. A similar approach was adopted recently by Scoutaris et al (CrystEngComm, 2016,18, 5079-5082) for high throughput screening of 
pharmaceutical cocrystals of Indomethacin and Saccharin. Different parameters were investigated, such as solvent drug–coformer stoichiometric 
ratios, solvent grade and solid content amounts while the cocrystals obtained were subsequently characterised by DSC, XRPD and FT-IR. 
An inspiring and pioneering work from Bradley’s group15 linked for the first time a high throughput 2D printing technique with the crystallization 
screening of commercial drugs. In their work, carbamazepine, sulfamethoxazole and 2-[(2-nitrophenyl) amino]-3-thiophenecarbonitrile were 
printed onto a microarray of hundreds of commercial polymers in order to generate or trigger different polymorphic forms. Raman spectroscopy 
was successfully used to characterize different polymorphic forms, although the crystal habits of the API solids were demonstrated to be a poor 
indicator of polymorphic form. Nonetheless, it was reported that 27 µg of each polymer-support and 1 mg (around ca. 15 µg/dry spot) of the 
selected drugs were enough to achieve rapid and effective solid form screening. Moreover, inkjet technology has recently aroused interest as an 
alternative drug formulation method16 and for preparing medicines by printing the active pharmaceutical ingredients (APIs). Inkjet printing 
encompasses a range of versatile, inexpensive fully automated methods to place small liquid drops with high precision onto a surface.17 A 
plethora of different materials have been successfully printed by inkjet including cells,18 colloids,19 curable-antifouling monomers,20 genes21,22 or 
proteins,23 polymers24 and screening of polymer features such as polymer functionalities or compositions for determining  materials  suitability in 
microarray manufacturing,25  nanomaterials and pharmaceutical formulations.26,27 Inkjet printing technology has been exploited particularly in the 
broad areas of new biomaterials28 and drug discovery, namely combinatorial chemistry and high-throughput screening,17,29 but not yet, in the 
screening of amorphous solid dispersions. As depicted, the main limitations in the screening of drug: polymer formulations reside not only in the 
scaling-down the amount of materials but also minimization of storage space. Therefore, we propose here a new screening process capable of 
combining all the advantages of the previous screening methods, namely, the miniaturization,8 the addressability and high-throughput.15 Six GFAI 
drugs were adopted in the present work, due to their ability to easily crystallize during preparation and storage of formulations.  The GFA1 class 
of drugs can be considered the most challenging to formulate as solid dispersions, hence are ideal model molecules to discriminate in the ability 
of polymers to inhibit crystallization. We have chosen PVPVA since it is available commercially, is low cost, widely used in literature for this 
aim, marketed in solid dispersions (KALETRA©) and present as a common polymer in the literature of interest. Briefly, three different 
nano/micro arrays were printed onto gold sputtered glass slides. The first array was developed in order to evaluate drug recrystallization tendency 
at different printed amounts by depositing DMSO solutions of pure drugs and PVPVA as a polymer reference in volumes ranging from 2.5 to 
65nL. The second array was produced by printing blends at different weight/weight ratios of the six drugs and PVPVA. Once the threshold 
printed amount required to characterize bulk behaviour was assessed, the third array was produced to establish a literature comparison and 
complete the validation. We hope that this will also lead to the development of useful methodology to analyze solid dispersions for their bulk 
behaviour.  
Materials and Methods 
Caffeine (CAF) (CAS 58-08-2), Flutamide (FLU) (CAS 13311-84-7) and Flufenamic acid (FLA) (CAS 530-78-9) were purchased from SIGMA-
ALDRICH (UK). Mefenamic acid (MEF) (CAS 61-68-7) and Finasteride (FIN) (CAS 98319-26-7) were obtained from Alfa Aesar (US, Ward 
Hill, MA). Carbamazepine (CBZ) (CAS 298-46-4) was purchased from MP Biomaterials, LLC (France). All drugs were used as received. 
Acetone HPLC grade, used in the bulk experiments, and Dimethylformamide HPLC grade were obtained from Fisher (UK). 
Polyvinylpyrrolidone-vinyl acetate copolymer or Copovidone64 as Kollidon®64 (PVPVA) was used as received from BASF. 
Polyvinylpyrrolidone (PVP), (Hydroxypropyl)methyl cellulose (HPMC), Poly-(acrylic) acid (PAA) and Dimethyl sulfoxide (DMSO) were 
purchased from SIGMA-ALDRICH and the latter used as a common solvent to dissolve all the printable materials and their blends. Gold 
sputtered slides were prepared employing a Leica EM SCD005 coating unit.  The sputtering chamber was filled with Argon, subsequently, a layer 
of 10-20 nm of gold was deposited onto the glass slide under vacuum at 25 Volt resulting in an average contact angle of 43.5 ± 0.5. This 
procedure provides a surface with a higher contact angle compared to bare glass limiting DMSO droplet splashing and is cheaper than commercial 
gold-coated glass slides. Polymer and drug solutions in DMSO were separately deposited on gold sputter-coated microscope slides, with a piezo 
electric inkjet printer (Sciflexarray S5, Scienion) using a 90 µm orifice nozzle. The droplet size was controlled by the values of the voltage and 
electrical pulse. In a routine experiment DMSO solution droplets with nominal volumes ranging from 250-280 pl, were dispensed at a 3 kHz 
jetting frequency by adjusting the voltage and pulse between 98-105 Volt  and 45-55 µs  respectively. The nozzle was washed with DMF in 
between each printing cycle, as part of the automated printing-washing loop. Printed DMSO solutions were allowed to evaporate overnight in the 
printer cage at around 25 °C and 55 % of RH and subsequently stored in a desiccator avoiding moisture contamination. DMSO normally 
evaporates in a time frame of 100-120 minutes for the biggest printed droplets (around 65-70 pl). DMSO was chosen both due to its high 
evaporation point that avoids clogging of the printer nozzle and also because it acts as a common solvent for all the drugs and polymers used in 
this study. The resulting dried spots, comprising variable amounts of polymer and drug from 25 up to 700 ng, were investigated using an 
Advanced Polarizing Microscope (HS1 microscope), Prior LuxPOLTM with 12V and 30W halogen lamp with variable brightness control to 
analyze the crystallinity of the drugs in these amounts. All the printed solid spots and the formulated powders were analyzed by POM30 which has 
been adopted as a routine benchmark analytical technique in the pharmaceutical field, to detect drug-recrystallization quickly. 
 
Microarray development 
A schematic representation of drug/polymer solution preparation and printing is shown in Figure 1. The initial drug and PVPVA stock solutions 
were prepared by simply dissolving the drugs and PVPVA separately in DMSO, in order to reach a final concentration of 10 mg/ml. High 
solubility of all the tested materials was found at this concentration. All the solutions were subsequently pipetted into a 384-well plate, used as the 
cartridge of the printer system. Three different microarrays were developed in order to decipher the best conditions to either predict drug:polymer 
bulk behaviour or align printed outcomes with pre-existing literature results. A first reference micro-array (1-PURE) was created to investigate 
how the pure formulation components behaved when printed onto the gold-coated slides. Secondly a drug:polymer micro-array was prepared 
from drug:PVPVA solutions as outlined above (2-DRUG:PVPVA array) For each of the six selected drugs (MEF, CBZ, FIN, FLU, CAF and 
FLA). A range of spot sizes (total formulation mass 25-28, 125-140, 625-700 ng) were used to allow direct comparison with the micro-array 1-
PURE described earlier. Each drug was formulated at drug:polymer ratios of 5, 10, 15, 25, 50 % w/w drug:polymer. The “2-DRUG:PVPVA” 
array was printed by dispensing different volumes, namely, 10-50-250 droplets, in order to determine the optimum amount to predict the bulk 
behaviour.  The microarray procedure adopted was as follows: as a first step, the desired amount of PVPVA solution was printed onto the gold-
coated slides. Subsequently, the different drug solutions were printed onto the previously deposited polymer-DMSO droplets, to give 5/95, 10/90, 
15/85, 25/75 and 50/50 drug/polymer w/w% ratios. To reach this protocol two different methodologies were tried. In the first protocol, 10, 50 and 
250 droplets of DMSO solutions were printed. The slides were left overnight inside the printer cage, at around 55% relative humidity (RH) and 25 
°C in order to allow total DMSO evaporation.  After DMSO evaporation, drug crystallization was monitored by using POM after 1 day and 7 
days. The arrays were stored in a desiccator employing silica as drying agent, in order to prevent humidity affecting drug recrystallization. To 
dispense 6 pure drugs, PVPVA and the various blends, in triplicate in one single slide, the entire process required around 45 minutes and less than 
1.5 µg per drug. Secondly, the effect of premixing solutions upon drug crystallization was evaluated. Drug-polymer solutions were pipetted into a 
384-well plate to give solutions at 5/95, 10/90, 15/85, 25/75 and 50/50 drug/polymer w/w% ratios. This latter approach resulted in a longer 
process (at least 2 hours), using a more sustained volume of drug-polymer solutions, without showing any difference from the first array building 
approach. This was expected as the polymer solution does not evaporate and no polymer film is observed in the time required for printing. 
Additionally, the amount of DMSO added with the drug is enough to completely re-wet the spot area. The first and faster approach was therefore 
adopted for the present work.  
 
  
Figure1. Schematic representation of the sequential steps needed to develop a solid dispersion micro-array. (1) Drug and polymer DMSO 
solutions are separately prepared and pipetted into a well-plate. (2-3) PVPVA solution is firstly withdrawn by the printer nozzle and 
dispensed at the required amount at the desired slide surface location. (2-4) Subsequently the drug solutions are printed using the desired 
amount onto the polymer solution droplets. After evaporation of DMSO, (5) each solid spot was analyzed by POM.   
 
Evaluation of drug recrystallization of printed spots 
Crystallization was simply evaluated by POM, mainly employing a 4X or 10X objective. A simplified semi-quantitative categorization of the 
spots, produced in the present work, was adopted from the well-established method described by Eerdenbrugh and Taylor31 for spin-coated drug-
polymer films. As shown in Figure 2, different classes of relative degree of drug crystallization can be observed, despite the complexity and the 
wide variety of forms and shapes, (a) completely amorphous (‘‘AAAA’’), (b) some minor crystallisation observed (“AAAC”), (c) slightly 
crystalline (‘‘AACC’’), (d) mainly crystalline (‘‘ACCC’’), or (e) completely crystalline (‘‘CCCC’’). Due to the spot conformation, and the 
miniaturized size of each sample it was possible to observe the whole spot/blend with one snapshot. Spots were imaged with and without crossed 
polarized filters 1 and 7 days after printing. In this time-frame few variations in crystallization were found by POM throughout the set of arrays 
(an example is given in Figure 1SI). Exploiting this latter classification, and aligning to the pre-existing literature8,31 a further semi-quantitative 
numerical value was calculated and defined as the ‘amorphicity index percentage’ (AI%) of the drug-polymer spots. AI % is simply defined as the 
relative number of A’s counted in the categorizations of the various drug/polymer ratios and different time points, expressed as a percentage.8,31 
AI% can be applied for each drug:polymer spot or as an average amongst all the formulations of the same drug and polymer. A high value of AI% 
indicates a good relative ability of a particular polymer to keep a particular drug in an amorphous state, as AI% decreases the ability of the 
polymer to maintain the drug in an amorphous form drops as well. Due to the stability of the printed formulations in the present work the 
amorphicity index has only been assessed after 7 days (AI%-7D). This latter was analyzed for each spot. 
 
Bulk drug:PVPVA dispersion preparation and bulk validation 
To probe whether the crystallization/stable amorphous behaviour of the “2-DRUG:PVPVA” array can be further considered as predictive of bulk 
conditions, two drug/PVPVA ratios for each drug were selected for a scaled-up formulation. Solutions of pure drugs, pure PVPVA and mixtures 
at drug/PVPVA ratios of 10 and 50% w/w were prepared by dissolving a final total amount of 2 g of materials in 10-15 ml of acetone. Acetone 
was selected because, as for DMSO, it is an aprotic polar solvent but with a lower boiling point. Consequently, acetone evaporation time scale in 
bulk experiments was similar to DMSO evaporation from printed spots. Upon full powder dissolution, different volume aliquots were dispensed 
in glass vials. Solvent was removed by centrifugal-rotary-evaporation (at 25 °C) and the vials stored in desiccators under silica. Each sample was 
prepared in triplicate and the extent of recrystallization of the different scaled-up drugs was analyzed by POM.  
 
 
Figure2. Examples of different API recrystallization profiles are presented. All the pictures are reported both without (top part) and with 
(bottom part) a polarized filter. (i) AAAA stands for entirely amorphous, (ii) AAAC, mainly amorphous, (iii) AACC, mainly crystalline 
and (iv) CCCC, entirely crystalline. 
 
Literature Comparison 
In order to align the present printing methodology to the pre-existing literature a third microarray was produced (“3-FLA:LITERATURE” array) 
to match some formulations and weight ratios reported in work by Taylor’s group.8,12 In the 3-FLA:LITERATURE array : only spots formed by 
ca. 650 ng were printed for the literature comparison. Hence 3-FLA:LITERATURE array was shaped. Solutions of FLA and different polymers, 
namely, HPMC, PAA, PVP and PMMA as well as PVPVA, were printed both to further test the reported high throughput nano-miniaturized 
method and to compare with the already well established literature.8 Pure polymer and FLA solutions in DMSO were prepared and pipetted into a 
384-well plate. Polymer solutions were printed onto a gold coated glass slide and the FLA solution was printed upon the polymer-solution-
droplets to give final drug/polymer ratios of 10/90, 25/75, 40/60, 50/50, 60/40, 75/25 and 90/10 (w/w). After evaporation, all the spots were 
observed by POM. The calculated AI% was compared to the values previously published by Van Eerdenbrugh and Taylor.8  
 
Results and discussion 
Pure Drug and PVPVA microarray printing  
The first microarray contained only pure drug solutions printed at different volumes/number of droplets in order to evaluate the miniaturization 
effect upon drug recrystallization. In particular, different amounts of 6 different pure drugs were initially deposited onto the gold sputtered slides 
alongside PVPVA (Figure 2SI). Starting from solutions at 10 mg/ml spots with an average of 25-28 ng for 10 droplets (2.5-2.8 nl), 125-140 ng for 
50 droplets (12.5-14 nl) and 625-700 ng for 250 droplets (62,5-70,0 nl) were obtained in all the printing experiment controls. As depicted in 
Figure 2SI, the whole set of drugs showed recrystallization with different and unique patterns at each of the printed volumes, as expected from 
their previously established GFAI classification.8 On the other hand, as expected, PVPVA did not show any birefringence at any printed amount, 
as it is widely reported in the literature to exist in the amorphous state, as is common for many polymers.8,32,33  
 
Effect of spot size, drug:PVPVA ratio and time on drug recrystallization within PVPVA matrix 
An example of the different ng amount for drug:PVPVA in each solid spot is reported in Figure 3 a sub-array of the 2-DRUG:PVPVA array. 
From inspection of Figure 3 it is clear that the presence of crystals in the spots appears to be a function of both increasing drug loading and 
increasing spot size, with crystals much more prevalent in the spots to the lower right portion of the figure than at the upper left.  Despite the use 
of a similar final amount of drug and polymer mixture, there are differences in spot sizes. This was observed throughout all arrays and seems to be 
affected by the amount of crystallization, with greater crystallinity shrinking the spot size and amorphicity resulting in greater spread.  This may 
be due to a variation in properties such as variation of contact angle and the nature of different crystals. 
 
 
 Figure 3. Example of an array section, all the POM pictures are reported with the cross polarized filters in place. Pictures of all 
Finasteride-PVPVA spots at all the different ratios are depicted after 7 days from the solvent evaporation. As shown in each row there is 
the same amount of printed materials (25-28ng top row, 125-140ng center and 625-700ng bottom row) and in each column there are spots 
containing the same drug/polymer ratio.  
 
MEF, CBZ, FIN and FLA acid showed different recrystallization behaviour upon printing as a function of deposited volume and drug/polymer 
ratios adopted (Figure 4SI). CAF appeared to recrystallize at all the drug/polymer ratios and independently from the volume of solution deposited. 
In contrast, FLU showed full amorphicity at all the ratios and also at the highest ng amounts explored (Table 1SI). Full data are available in Fig 
4SI. Two examples of mixed recrystallization tendency are reported in Figure 4. For clarity and reasons of space, a vertical section at particular 
weight/weight % ratio of MEF:PVPVA and FIN:PVPVA formulations are reported in Figure 4. MEF did not show any evidence of 
recrystallization at any drug/polymer ratio up to 50 printed droplets, namely, 125-140 ng of final drug/polymer spot on the surface. Crystals were 
first observed only at 50% w/w and after printing an amount of formulation in the range 625-700 ng (Figure 4SI). On the other hand, FIN showed 
recrystallization, in a time frame of 1 day after printing, at 25-28 ng at a ratio of 15% w/w (Figure 4). For the two latter MEF and FIN 
formulations, taken as examples, higher final volumes between 125 and 140 nl (final spot containing around 1.5 µg of drug and polymer) were 
dispensed in order to check whether spots of around 650 ng are the minimum amount needed for bulk behaviour. As shown in Figure 4 the same 
trend evaluated for 62.5-70 nl was observed with 125-140 nl (example in Figure 4).  
  
  
 
 
 
 
 
 
 
Figure 4. Section of MEF:PVPVA and FIN:PVPVA subarrays showing examples of different recrystallization behaviour. Left column: 
Mefenamic Acid showed re-crystallization from PVPVA mixture at 50% w/w of concentration and final deposited volume threshold of 
62.5-70 nl. Right column: Finasteride phase segregated from PVPVA at a concentration of 15 % w/w showing the crystallization 
threshold at 2.5-2.8 nl. Final spot diameter may result from several variables such as amount of polymer, rate and extent of drug 
crystallization and polymer-surface interaction. 
  
This trend for larger spots with higher drug loading to crystallize earlier than the smaller spots with lower drug loading likely arises simply from 
the probability of nucleation being, to a first approximation, a function of the total number of drug molecules present in a spot. Physical 
separation of drug molecules by polymer will also reduce the nucleation probability in the samples with lower drug loading. Spots were depicted 
with and without polarized filters, 1 and 7 days after printing. However, in this time-frame few variations were found by POM throughout the set 
of arrays (MEF is reported as main example in Figure 1SI). Since the aim of the present work is mainly to develop a high throughput screening 
method for the prediction of the stability of solid dispersions regardless of the nature of the polymer drug pairs, we have not attempted to provide 
possible in depth explanations for particular experimental observations. In addition, by simply plotting the AI%-7D for each pair of drug:PVPVA 
it is easy to immediately establish differences of recrystallization amongst the selection of drugs within the PVPVA matrix (Figure 3SI). Taking 
into account the above drug/polymer experimental evidence, spots formed by 625-700 ng, were considered as the smallest required for evaluation 
of different drug recrystallization behavior within the polymer matrix. As an interesting first observation of the arrays, it is evident that each 
drug/polymer combination showed a threshold of amorphous stability at different w/w % ratios with little variation over time (MEF is reported as 
an example Figure 1SI). Moreover, for some stable spots amorphicity was also observed up to 25-50% drug loading (MEF, CBZ, FLU and FLA) 
(Figure 3SI). This latter evidence supports previous reported experimental observations where a printer was adopted to formulate PVP-Felodipine 
solid dispersions, which has shown an intimate mixing and homogeneity up to almost 70% of drug loading.34  
 
 Bulk prediction of drug:PVPVA formulations 
In order to assess ink-jet printing as a predictive technique to identify useful drug-polymer formulations suitable as solid dispersions, two 
drug:polymer ratios 10/90 and 50/50, were selected to be further analyzed for all the drug-like molecules, at a gram-scale. POM was adopted to 
evaluate the presence or absence of crystals inside the different solid dispersions without approximating any semi-quantitative ranking as reported 
for the printed samples. The bulk scale-up was carried out simply to assess the screening outcomes and compare recrystallization at both nano- 
and gram-scale. Dissolution of drug and polymer in acetone and removal by rotary evaporator to constant weight took around 60 to 90 mins. The 
temperature and the evaporation time frame was similar to that for evaporation of DMSO from the slide for 62.5-70 nl, that was of 100 to 120 
minutes. The resulting powders were stored in a desiccator for 7 days and then analyzed and compared to the selected spots.  All the formulated 
powders were rapidly analyzed by POM. 30 At ratios of 10/90, POM observation of the stored powders revealed that only the CAF formulation 
showed birefringence. No evidence of birefringence was found for the all the other 10/90 ratios, this matched with the printed samples, as seen in 
Figure 5A. At a ratio of 50/50 in the bulk samples, the POM observation showed no evident birefringence for FLU, fairly weak for CBZ and FLA 
whilst remarkable birefringence was obvious for all the other samples (Figure 5B). This mirrored the printed sample observations well, where 
only the FLU spot was completely amorphous while all the others showed small molecule recrystallization to various extents that was weak or 
particularly limited for CBZ and FLA, well visible for MEF and extensive in the cases of FIN and CAF (Figure 5).  
In the present work it has been found that a printed threshold of some 650 ng of physical blend is needed to align with bulk-gram scale re-
crystallization behaviour. 
  
  
 
Figure 5. 2-DRUG:PVPVA array POM pictures with polarized filters of printed dried spots compared to gram-scale powder samples.  
A. Amongst all the 10/90 samples only CAF10% showed birefringence, confirmed by the corresponding bulk sample. All the other 
formulations printed or bulk showed no birefringence. 
B. Both printed and bulk CAF50%, FIN50% and MEF50% formulations showed remarkable birefringence. Weak recrystallization 
of the printed CBZ50% and FLA50% was confirmed by POM of the corresponding bulk samples, while no birefringence was observed 
for FLU50% either as printed spot-ng sample or in gram quantity. 
   
Literature comparison of FLA:polymer formulations 
A comparison to the pre-existing literature was made. Taking into account the bulk prediction results, dry spots with an average of 650 ng of final 
blend were adopted.  In particular, FLA DMSO solution was printed at different ratios against PAA, HPMC, PVP and PVPVA solutions 
producing an array named 3-FLA:LITERATURE. The resulting dry spots were compared to previously published outcomes obtained by spin 
coating.8 AI% of each FLA formulation is reported in Table 2SI as a mean value for each ratio against the values reported in the literature. An 
average AI% for the different FLA/polymer pairings is reported and presented in Figure 6 to simplify the drug polymer compatibility rank and to 
easily evaluate differences with respect to the published data. The same AI% trend, PVP>PVPVA>HPMC>PAA, was found both in the 
experimental results collected in the present work and the previously published data6. In addition, in table 2SI both the AI% for each FLA 
formulation at each weight ratio mediated after 1 and 7 days and the AI% average are reported. The main advantage in the present work resides in 
the amount of material needed for analysis and prediction. In fact, for each formulation of FLA/polymer at all the seven explored ratios, a 
maximum of 2.4 µg was deposited against an approximate value of 5-15 mg following the methodology in the Taylor group papers.8,12 There are 
only minor differences between the two sets of data (Table 2SI), most likely due to the intrinsic differences between the two techniques used, 
resulting in a greater time to solidify the samples in the presently reported method which may lead to the slightly increased amount of 
crystallization seen. 
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Figure 6. Average AI% value for FLA-PAA, FLA-HPMC, FLA PVPVA and FLA-PVP printed in the present paper (black) and 
extracted from spin coated previously published data (red) are shown in the figure. The same stability-affinity trend was found 
comparing the two sets of data, in particular, PVP>PVPVA>HPMC>PAA.  
 
While relatively small numbers of drugs and polymers were used for the present work, 400-500 spots can be readily accommodated on a single 
microscope slide, and these can be printed at a rate of approximately 1000spots per hour.  POM analysis and making a photographic record of a 
single slide could be accomplished in about 45minutes. Reproducibility is within 5-10 AI%. This new technique might be exploited, not only to 
save precious or unknown/newly synthesized organic compounds, but also to reduce the assay space to just few slides and facilitate much more 
rapid sample preparation and analysis. Taken together, the tailored flexibility in terms of materials and solvents adopted,35 high degree of 
automation and speed of execution36 combined with low error37 and wastage,17 inkjet printing thoroughly meets all the characteristics and 
demands for a high-throughput-miniaturized screening approach not only in the drug-solid dispersion field but in all those areas where 
recrystallization needs to be evaluated. 
Conclusions  
In the present work, ink-jet technology was exploited for the first time to build nano-arrays to determine drug nucleation within a polymeric 
matrix (PVPVA). Drug nucleation was investigated with respect to the amount of drug mixture required, the drug/polymer ratio and assessed with 
respect to the existing methodology and literature.  , It was noted that, after solvent evaporation, drug nucleation can be triggered by either the 
final amount of drug printed (bulk amount) or to the ratio of drug with respect to the polymer, (due to incompatibility of the drug inside the 
polymer matrix). It was observed that, for the reported set of drug:PVPVA, spots with a final quantity of 650 ng of materials provided a high 
correlation of screening compared to the behaviour of gram scale drug-polymer blend.   This screening ability was further assessed against 
literature data produced by spin coating with solvent fast evaporation. In the 3-FLA:LITERATURE array PVPV, PVPVA, HPMC and PAA were 
mixed at different w/w% ratios with FLA, printed by producing final dry spots of ca. 650 ng of final blend and compared with AI% values 
extracted from the literature. The same trend of amorphicity stability was found, in particular, PVP>PVPVA>HPMC>PAA. In the printed array 
2-DRUG:PVPVA an average of 390 ng (10 and 50% of drug) were used, hence, <0.05% sample than a bulk experiment, where around 1.1 g were 
used, showing that the screening process was not just high throughput, but also very sparing on use of precious material.  The entire array was 
printed in triplicate in less than 45 min in a fully automated way. Using the final format (an average spot of 65-70 nl)  DMSO evaporation was 
about 100 to 120 min, and it is possible to start POM evaluation immediately after this, making the nanoprocedure very rapid and efficient. 
Furthermore, the extended amorphous lifetime obtained by printing amounts ranging between 25 and 140 ng, might lead to future applications. 
An interesting idea might be to use manufacturing technologies such as 3D printer to separate drug/polymer into small restricted and defined areas 
and coating of small devices. It might facilitate a better understanding of the drug/polymer interactions leading to more predictable and more 
stable polymer dispersions. Finally, it might be considered as an easy and powerful method to assess nucleation probability in both drug:polymer 
blends and for pure drugs, which is possible with a final printed material amount well below 1 µg. 
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Supplementary information 
Table 1. Number of A and C values for each drug/polymer blend at all the w/w% ratios after 7 days. 
Drug 
Drug/PVPVA w/w% AI%-7D 
5% 10% 15% 25% 50% 
Flutamide AAAA AAAA AAAA AAAA AAAA 100 
Carbamazepine AAAA AAAA AAAA AAAA AAAC 95 
Flufenamic AAAA AAAA AAAA AAAA AAAC 95 
Mefenamic AAAA AAAA AAAA AAAA AACC 90 
Finasteride AAAA AAAA AAAC AACC CCCC 60 
Caffeine  AAAC AACC AACC CCCC CCCC 35 
 
As depicted from the table, it is possible to evaluate the extent of amorphicity for each drug/polymer spot and easily calculate the AI% -7D average to determine differences of stable amorphous 
miscibility. The table was produced considering only spots formed for a volume between 60-70 nl. 
 
 
 
 Figure 1SI. PVPVA/MEF blends at 15, 25 and 50% w/w ratios after 1day (top row) and 7 days (bottom row) were selected to show both an example of “A” degree due to polymer/drug 
ratios and the variation of AI% with time. Printed volume ranged from 62.5 to 70 nl (625-700 ng of final materials present on the slide). 
 
 
 
  
Figure 2SI. Pure drugs and PVPVA microarray depicted by POM with the polarizing filters on. From the top line: spots produced by depositing a volume solution between 2.5-2.8 nl (25-28 ng). 
Middle line: spots printed using 12.5-14 nl (125-140 ng). Bottom line: spots printed with a volume ranging 62.5-70 nl (625-700 ng). All the drugs but not the amorphous polymer show a 
characteristic birefringent pattern. In fact, PVPVA is barely visible with the polarizing filters on.
  
34 
 
 
 
 
 
 
 
 
 
 
Figure 3SI. All the drugs showed an AI%-7D above 50% apart from CAF that re-crystallized easily at all the ratios with a 
final AI% of 35%.  
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Figure 4SI. Drug-PVPVA spot array POM pictures, varying both printed amount (number of droplets) and drug polymer ratio.  
 
 
Table 2SI. AI% of FLA against PAA, HPMC, PVPVA and PVP, at each w/w% ratio and as final average. The AI% for each 
drug\polymer formulation was calculated as an average between day 1 and 7. 
 
 10/90 
AI% 
1-7days 
25/75 
AI% 
1-7days 
40/60 
AI% 
1-7days 
50/50 
AI% 
1-7days 
60/40 
AI% 
1-7days 
75/25 
AI% 
1-7days 
90/10 
AI% 
1-7days 
Average 
AI% 
FLA/PAA 
25 25 0 0 0 0 0 7 
25 25 0 0 0 0 0 7 
FLA/HPMC 
100 100 100 50 25 0 0 54 
100 100 100 100 25 0 0 61 
100 100 100 75 50 0 0 61 
  
40 
FLA/PVPVA 
100 100 100 100 100 63 0 80 
FLA/PVP 
100 100 100 100 75 25 0 71 
100 100 100 100 100 100 0 86 
In the table both experimental (black) and literature (red) AI% values are reported. It is possible to exploit AI% to follow the 
presence of amorphicity stability trends amongst both polymers and between data generated by printing and literature results. 
 
